In summary, to sum up, PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 has a good and safe effect on SCLC patients, develops and improves the body's cellular immune function, adjusts the level and expression of tumor markers, improves the body's material metabolism, and restores the body's yin and yang imbalance. The gene discussed is RPL17; the disease is lung cancer.